Vineet Laboratories Ltd.
37.19
INR
-0.83
(-2.18%)
Vineet Laboratories Ltd.
NSE:VINEETLAB
(National Stock Exchange of India)
Recent
price
37.19
P/E
ratio
31.51
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Vineet Laboratories Limited (VINEETLAB.NS) is an India-based pharmaceutical company that designs, develops, manufactures, and sells active pharmaceutical ingredient (API) intermediates, bulk drugs, and fine chemicals. The company produces API intermediates including Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine; fine chemicals and reagents such as IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, and Aminouracil; and custom synthesis molecules for multinational clients. Incorporated in 2016 and headquartered in Hyderabad, Telangana, with manufacturing facilities in Malkapur Village, Yadadri Bhuvanagiri District, the ISO 9001:2015-certified firm operates a multipurpose plant equipped for complex reactions, including low-temperature processes down to -100°C and handling pyrophoric chemicals. It serves domestic and international customers in the healthcare and pharmaceuticals sectors, exporting products to markets including the United States and exporting to clients such as Gilead Sciences and Teva. In recent developments, Vineet Laboratories approved a rights issue in November 2025 to raise Rs. 3,000 lakhs, forming a Rights Issue Committee to oversee the process. The company held its 9th Annual General Meeting on September 25, 2025, following dispatch of the 2024-25 annual report, and in August 2025, its board approved a postal ballot for increasing authorized share capital, raising loan/guarantee/investment thresholds, and appointing Mr. Premananda Reddy Vennapusa as a non-executive director. Promoter holdings decreased in recent quarters, with disclosures of share sales by promoters including Mr. Gaddam Venkata Rama and Mr. Satyanarayana Raju Bhupathiraju in August 2025. These moves follow the company's demerger from Ortin Laboratories Limited's API Intermediates Division in December 2020, enhancing its focus on pharmaceutical intermediates and process technology outsourcing.